TGF-beta in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.

Abstract:

Liver fibrosis is an advanced liver disease condition, which could progress to cirrhosis and hepatocellular carcinoma. To date, there is no direct approved antifibrotic therapy, and current treatment is mainly the removal of the causative factor. Transforming growth factor (TGF)-beta is a master profibrogenic cytokine and a promising target to treat fibrosis. However, TGF-beta has broad biological functions and its inhibition induces non-desirable side effects, which override therapeutic benefits. Therefore, understanding the pleiotropic effects of TGF-beta and its upstream and downstream regulatory mechanisms will help to design better TGF-beta based therapeutics. Here, we summarize recent discoveries and milestones on the TGF-beta signaling pathway related to liver fibrosis and hepatic stellate cell (HSC) activation, emphasizing research of the last five years. This comprises impact of TGF-beta on liver fibrogenesis related biological processes, such as senescence, metabolism, reactive oxygen species generation, epigenetics, circadian rhythm, epithelial mesenchymal transition, and endothelial-mesenchymal transition. We also describe the influence of the microenvironment on the response of HSC to TGF-beta. Finally, we discuss new approaches to target the TGF-beta pathway, name current clinical trials, and explain promises and drawbacks that deserve to be adequately addressed.

Citation: Cells. 2019 Nov 11;8(11). pii: cells8111419. doi: 10.3390/cells8111419.

Date Published: 11th Nov 2019

Authors: B. Dewidar, C. Meyer, Steven Dooley, A. N. Meindl-Beinker

Help
help Creator
Activity

Views: 333

Created: 8th Jan 2020 at 16:08

help Attributions

None

Related items

Powered by
(v.1.9.0)
Copyright © 2008 - 2019 The University of Manchester and HITS gGmbH